Abd El-hafez, F., Nsr-Allah, A., Mohamed, A., Ahmed, A., Mahmoud, A. (2021). Novel Biomarker Serum Calprotectin for Early Diagnosis of Diabetic Peripheral Neuropathy in Type 2 Diabetes Patients. The Egyptian Journal of Hospital Medicine, 82(2), 379-385. doi: 10.21608/ejhm.2021.144904
Farid Fawzy Abd El-hafez; Ayman Abd-Elrahman Mohamed Nsr-Allah; Ahmed Kamal Abd Eljalil Mohamed; Azza Moustafa Ahmed; Amira Ahmed Mahmoud. "Novel Biomarker Serum Calprotectin for Early Diagnosis of Diabetic Peripheral Neuropathy in Type 2 Diabetes Patients". The Egyptian Journal of Hospital Medicine, 82, 2, 2021, 379-385. doi: 10.21608/ejhm.2021.144904
Abd El-hafez, F., Nsr-Allah, A., Mohamed, A., Ahmed, A., Mahmoud, A. (2021). 'Novel Biomarker Serum Calprotectin for Early Diagnosis of Diabetic Peripheral Neuropathy in Type 2 Diabetes Patients', The Egyptian Journal of Hospital Medicine, 82(2), pp. 379-385. doi: 10.21608/ejhm.2021.144904
Abd El-hafez, F., Nsr-Allah, A., Mohamed, A., Ahmed, A., Mahmoud, A. Novel Biomarker Serum Calprotectin for Early Diagnosis of Diabetic Peripheral Neuropathy in Type 2 Diabetes Patients. The Egyptian Journal of Hospital Medicine, 2021; 82(2): 379-385. doi: 10.21608/ejhm.2021.144904
Novel Biomarker Serum Calprotectin for Early Diagnosis of Diabetic Peripheral Neuropathy in Type 2 Diabetes Patients
Background: Calprotectin was identified as an endogenous activator of Toll-like receptor 4 (TLR4) and as receptor for advanced glycation end product (RAGE). Elevated plasma levels of calprotectin have been reported in a variety of chronic inflammatory conditions. Elevated calprotectin levels have been reported to predict microvascular alterations in type 2 diabetes (T2DM) patients. Objective: To make an up to date review of serum level of calprotectin as a predictor for early diagnosis of peripheral neuropathy in type 2 diabetes patients. Patients and methods: A total number of 90 subjects were included in the study after fulfillment of the inclusion and exclusion criteria. Calprotectin was measured for all the 90 subjects. Results: Serum calprotectin levels were significantly higher in group III “diabetics with neuropathy” compared to group II “diabetics without neuropathy “and group I “healthy controls”. Conclusion: High levels of calprotectin were detected in type 2 diabetic patients with peripheral neuropathy.
View on SCiNiTO
Top